About TEZCAT Laboratories:
TEZCAT Laboratories is an early-stage biopharmaceutical company developing innovative therapies for RAS-mutant cancer patients. The TEZCAT core technology is a protein-based therapeutic delivery platform that penetrates, accumulates in, and is internalized specifically by RAS tumors using a novel escape-resistant targeting mechanism. TEZCAT's lead asset, TZT-102, is currently being developed through support by two NIH/NCI STTR Phase I awards.
Born out of NYU Langone Health, our team is committed to refining and delivering the leading-edge technology from bench to bedside. TEZCAT Laboratories has participated in the following programs:
TEZCAT Laboratories is an early-stage biopharmaceutical company developing innovative therapies for RAS-mutant cancer patients. The TEZCAT core technology is a protein-based therapeutic delivery platform that penetrates, accumulates in, and is internalized specifically by RAS tumors using a novel escape-resistant targeting mechanism. TEZCAT's lead asset, TZT-102, is currently being developed through support by two NIH/NCI STTR Phase I awards.
Born out of NYU Langone Health, our team is committed to refining and delivering the leading-edge technology from bench to bedside. TEZCAT Laboratories has participated in the following programs:
- 2021 TMC Accelerator for Cancer Therapeutics, part of TMC Innovation and funded by Cancer Prevention and Research Institute of Texas (CPRIT)
- 2020 JLABs Virtual Program, part of Johnson & Johnson Innovation
- 2018 Entrepreneurship Lab (ELab) Program, an initiative of NYC's Economic Development Corporation (NYCEDC).
